Founded in 1998 by President and CEO Waleed Hassanein, TransMedics Group (NASDAQ: TMDX) has quickly become one of the easiest stocks to root for of our time by revolutionizing the organ donation and transplant process.

TransMedics held its initial public offering (IPO) in 2019 and saw its stock rise over 300% by 2023. However, in the last three months, its stock price has plummeted over 55% as the market wrestled with TransMedics' recent mergers and acquisitions (M&A) activity.

This has left investors at a crossroads. Is the company a falling knife, forced to rely upon M&A to grow? Or is TransMedics quietly transforming the organ transplant industry and actively building upon its first-mover advantage?

Continue reading

Source Fool.com